Comparative Pharmacology
Head-to-head clinical analysis: VIADUR versus ZOLADEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VIADUR versus ZOLADEX.
VIADUR vs ZOLADEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist that stimulates pituitary gonadotropin release initially, followed by sustained suppression of pituitary gonadotropins due to receptor desensitization, leading to reduced testosterone production.
Gonadotropin-releasing hormone (GnRH) agonist; initially stimulates and then suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, leading to reduced sex steroid production.
Leuprolide acetate implant 65 mg implanted subcutaneously in the inner aspect of the upper arm once yearly.
3.6 mg subcutaneously every 28 days (prostate cancer, endometriosis) or 10.8 mg subcutaneously every 12 weeks (prostate cancer).
None Documented
None Documented
The terminal elimination half-life of leuprolide acetate following subcutaneous administration is approximately 3 hours. In patients with renal impairment, half-life may be prolonged; however, no dose adjustment is recommended for mild-to-moderate impairment.
Approximately 4.2 hours (subcutaneous); due to continuous release from depot formulation, effective half-life is extended to ~28 days.
Leuprolide acetate is primarily eliminated via hepatic metabolism and renal excretion. Approximately 48% of the dose is recovered in urine over 24 hours, with 5% as unchanged drug. Fecal excretion accounts for about 5%.
Primarily renal (approximately 20% as unchanged drug); remainder as metabolites via biliary/fecal (approximately 80%).
Category C
Category C
GnRH Agonist
GnRH Agonist